0001209191-23-032731.txt : 20230526 0001209191-23-032731.hdr.sgml : 20230526 20230526210035 ACCESSION NUMBER: 0001209191-23-032731 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230525 FILED AS OF DATE: 20230526 DATE AS OF CHANGE: 20230526 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tross Stuart A CENTRAL INDEX KEY: 0001589641 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50865 FILM NUMBER: 23971167 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320-1799 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MANNKIND CORP CENTRAL INDEX KEY: 0000899460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133607736 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 CASPER STREET CITY: DANBURY STATE: CT ZIP: 06810 BUSINESS PHONE: 818-661-5000 MAIL ADDRESS: STREET 1: 1 CASPER STREET CITY: DANBURY STATE: CT ZIP: 06810 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-05-25 0 0000899460 MANNKIND CORP MNKD 0001589641 Tross Stuart A 1 CASPER STREET DANBURY CT 06810 0 1 0 0 Chief People & Workpl Officer 0 Common Stock, $.01 Par Value 2023-05-25 4 A 0 92000 0.00 A 1024752 D Performance Restricted Stock Unit 2023-05-25 4 A 0 113000 0.00 A Common Stock, $.01 Par Value 113000 113000 D Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested. The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. /s/ Stuart Tross 2023-05-26